Radioimmunoassay of Eicosanoids: Its Application in the Development of Anti-Inflammatory and Analgesic Drugs

  • Frank Carey
  • Duncan Haworth
  • Robert A. Forder
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 18 A)

Abstract

Membrane-bound avachidonic acid is a precursor for PG and LT biosynthesis*. Members of this family of autocoids have been implicated in pathophysiology including regulation of microvascular blood flow and permeability, leukocyte chemotaxis, hyperalgesia and anaphylaxis. Consequently, in recent years considerable effort has been expended in the search for agents that block the synthesis and antagonize the actions of these autocoids. Most of the biologically stable arachidonic metabolites can now be measured by RIA, and this technique finds widespread use in the search for AI and analgesic drugs. Within a mechanistic approach to new drug development, RIA of eicosanoids can be used at the pre-clinical and clinical stages of drug development and now plays an integral part in hypothesis testing and in the progression of pharmacological curiosities to effective medicines.

Keywords

Analgesic Drug Sodium Salicylate Microvascular Blood Flow Inflammatory Exudate Peritoneal Lavage Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviation

(NS)AI(D)

(non-steroidal) anti-inflammatory (drug)

HETE

hydroxy-eicosatetraenoic acid

LT

leukotriene

PG

prostaglandin

MS

mass spectrometry

RIA

radioimmunoassay

RP

reversed phase

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Granström, E. & Kindahl, H. (1979) Adv. Prostagl. Thrombox. Res. 5, 119–210.Google Scholar
  2. 2.
    Carey, F., Forder, R.A., Gibson, K.H. & Haworth, D. (1988) Prostaglandins Leukotrienes & Med., in press.Google Scholar
  3. 3.
    Young, R.N., Kakushima, M. & Rokach, J. (1982) Prostaglandins 23, 603–613.CrossRefGoogle Scholar
  4. 4.
    Levine, L., Morgan, R.A., Lewis, R.A., Austen, K.F., Clark, D.A., Marfat, A & Corey, E.J. (1981) Proc. Nat. Acad. Sci. 78, 7692–7696.CrossRefGoogle Scholar
  5. 5.
    Vermylen, J., Defreyn, G., Carreras, L.O., Machin, S.J., Van Schaeren, J. & Verstraete, M. (1981) Lancet i, 1073–1075.CrossRefGoogle Scholar
  6. 6.
    Maguire, E.D. & Wallis, R.B. (1983) Thrombosis Res. 32, 15–27.CrossRefGoogle Scholar
  7. 7.
    Randall, M.J. & Wilding, R.I.R. (1982) Thrombosis Res. 28, 607–616.CrossRefGoogle Scholar
  8. 8.
    Carey, F. & Haworth, D. (1986) Prostaglandins 31, 47–59.Google Scholar
  9. 9.
    Carey, F., Forder, R.A. Haworth, D. & Woollard, P.M. (1987) Biochem. Soc. Trans. 15, 430–431.Google Scholar
  10. 10.
    Carey, F., Forder, R.A. & Haworth. D. (1987) Br. J. Pharmacol. 91, 404P.Google Scholar
  11. 11.
    McMillan, R.M., Millest, A.J., Proudman, K.E. & Taylor, K.B. (1986) Br. J. Pharmacol. 87, 53P.Google Scholar
  12. 12.
    Carey, F. & Forder, R.A. (1986) Prostaglandins Leukotrienes Med. 22, 57–60.CrossRefGoogle Scholar
  13. 13.
    Carey, F., Haworth, D., Edmonds, A.E. & Forder, R.A. (1988) J. Pharmacol. Meths., in press.Google Scholar
  14. 14.
    Haworth, D. & Carey, F. (1985) in Inflammatory Mediators (Higgs, G.A. & Williams, T., eds.), Macmillan, Basingstoke, pp. 37–45.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Frank Carey
    • 1
  • Duncan Haworth
    • 1
  • Robert A. Forder
    • 1
  1. 1.Research Department IIICI Pharmaceuticals plcMacclesfieldUK

Personalised recommendations